For clinic directors and healthcare decision-makers evaluating new diagnostic capabilities, cerebrovascular reactivity (CVR) assessment represents one of the most clinically significant — and underutilized — tools in modern neurology. As the evidence base grows linking impaired CVR to stroke risk, traumatic brain injury (TBI) outcomes, and cognitive decline, the question is no longer whether to measure CVR, but how to do it efficiently, accurately, and at scale.

Transcranial Doppler (TCD) ultrasound has emerged as the leading non-invasive modality for real-time CVR assessment — and automated TCD platforms like the NeuraSignal NG2 Intelligent Ultrasound are making it more accessible than ever for clinics of all sizes.

What Is Cerebrovascular Reactivity?

Cerebrovascular reactivity — also referred to as vasomotor reactivity (VMR) — is the ability of cerebral blood vessels to dilate or constrict in response to metabolic stimuli, particularly changes in arterial carbon dioxide (CO₂) levels. In simple terms, CVR measures how well the brain’s vascular system can regulate blood flow and maintain adequate perfusion under varying physiological conditions.

This autoregulatory capacity is essential for brain health. When cerebral vessels lose their ability to respond appropriately to CO₂ fluctuations, the brain becomes vulnerable to ischemic events, hemodynamic instability, and progressive neurological damage.

Critically, impaired CVR has been identified as an independent risk factor for ischemic stroke and is increasingly recognized as a biomarker of overall brain health. Research demonstrates its prognostic value for both stroke risk stratification and cognitive decline, making it a powerful clinical tool for early intervention.

Why TCD Is the Preferred Modality for CVR Assessment

First described by Aaslid and colleagues in 1982, Transcranial Doppler ultrasound is a non-invasive method for evaluating cerebral blood flow by measuring flow velocities in the basal arteries of the brain. Since its introduction, TCD has become one of the most commonly utilized methods for intracranial monitoring in critically ill patients and the most popular non-invasive cerebral monitoring modality available.

For clinic directors weighing diagnostic investments, TCD offers several compelling advantages over alternative imaging methods like MRI-based CVR assessment:

Non-invasive and radiation-free: No contrast agents, no ionizing radiation, and no surgical intervention required — reducing patient risk and improving compliance.
Real-time, continuous monitoring: TCD allows bilateral recording of cerebral blood flow velocity through major arteries, particularly the middle cerebral artery (MCA), providing dynamic data rather than static snapshots.
Portable and bedside-capable: TCD machines are compact and mobile, enabling evaluations in critical care units, emergency rooms, outpatient clinics, and even during surgical procedures.
Cost-effective: Compared to MRI or CT angiography, TCD exams are significantly less expensive to perform and require less infrastructure.
Well-tolerated across populations: TCD is well-tolerated even by aged and cognitively impaired individuals, making it ideal for dementia screening and geriatric neurology applications.

These characteristics make TCD particularly attractive for clinics looking to expand their cerebral hemodynamic monitoring capabilities without the overhead of advanced imaging suites.

How CVR Is Measured with TCD

CVR assessment using TCD involves measuring changes in MCA blood flow velocity in response to a vasodilatory or vasoconstrictive stimulus. Several well-validated methods exist, each with distinct clinical advantages:

CO₂ Inhalation (Hypercapnia): The patient breathes a controlled mixture of CO₂ and O₂ to induce cerebral vasodilation. This method has demonstrated the highest reproducibility for CVR assessment and is considered the gold standard in research settings.

Breath-Holding Test (BHT): A simple, well-tolerated bedside method where the patient holds their breath for approximately 30 seconds, causing endogenous CO₂ buildup. The resulting change in MCA velocity is expressed as the Breath-Holding Index (BHI). Recent research has identified the BHI as the most accurate and robust metric of CVR for predicting mild cognitive disorders, with an area under the curve (AUC) of 0.827.

Hyperventilation (Hypocapnia): Voluntary hyperventilation reduces CO₂ levels and induces vasoconstriction, testing the vasoconstrictive reserve of cerebral vessels.

Acetazolamide Administration: An intravenous pharmacological vasodilatory stimulus that provides a standardized challenge for CVR measurement.

For clinics seeking practical, scalable CVR assessment, the Breath-Holding Test stands out for its simplicity — it requires no specialized gas mixtures or IV medications, can be performed at the bedside, and has strong predictive validity.

Clinical Applications: Where CVR Assessment Delivers Value

Stroke Risk Prediction and Carotid Disease

For patients with carotid artery stenosis or occlusion, CVR assessment via TCD provides critical prognostic information. Research has shown that severely impaired cerebrovascular reactivity independently predicts stroke and transient ischemic attack (TIA) risk in these patients. This means CVR testing can help clinicians identify high-risk individuals who may benefit from more aggressive intervention — such as carotid endarterectomy or stenting — versus those who can be managed conservatively.

For stroke programs and vascular neurology clinics, adding TCD-based CVR assessment strengthens the diagnostic workup and supports more personalized treatment planning. Combined with other TCD clinical applications like emboli detection and PFO screening, CVR testing creates a comprehensive cerebrovascular assessment capability.

Traumatic Brain Injury (TBI) Monitoring

Disruption of cerebrovascular reactivity following TBI has been documented since the 1970s, and TCD-based continuous time-domain indices of CVR — such as the mean flow index (Mx) — have demonstrated significant prognostic utility for functional outcomes following TBI. Recent studies indicate that systolic flow velocity-based indices may contain the most prognostic value for predicting patient recovery.

In neurocritical care settings, continuous TCD monitoring of CVR helps clinicians assess the brain’s autoregulatory status in real time, guiding decisions about blood pressure management, sedation, and surgical intervention. For hospitals with trauma programs or neuro ICUs, this capability can directly impact patient outcomes and length of stay.

Dementia and Alzheimer’s Disease Evaluation

One of the most promising emerging applications of CVR assessment is in the evaluation of dementia and Alzheimer’s disease. Research has demonstrated that vasomotor reactivity is significantly reduced in patients with Alzheimer’s disease compared to age-matched controls — 24.5% vs. 36.6% on the right MCA and 20.7% vs. 34.1% on the left MCA.

Reduced cerebrovascular reactivity has been shown to predict cognitive decline in Alzheimer’s patients, and the pulsatility index combined with spontaneous emboli detection via TCD are among the best discriminators of dementia from normal aging. Perhaps most significantly, CVR assessed by BHI has been identified as a predictor of conversion from mild cognitive impairment (MCI) to dementia — offering a window for early intervention.

For clinics serving aging populations, TCD-based CVR assessment provides a practical, non-invasive screening tool that can be integrated into routine cognitive health evaluations.

Neurocritical Care Applications

In subarachnoid hemorrhage (SAH) and TBI, TCD-based CVR monitoring helps assess delayed cerebral ischemia risk and guides interventions such as induced hypertension or vasodilatory therapy. The ability to perform continuous bedside monitoring without transporting critically ill patients to imaging suites is a significant operational advantage. The NeuraSignal Platform’s hemodynamic monitoring capabilities are specifically designed for these demanding clinical environments.

Why Automated TCD Changes the Equation for Clinics

Historically, one of the barriers to widespread TCD adoption has been operator dependency. Traditional TCD requires a skilled sonographer to locate the temporal acoustic window, identify the target vessel, and maintain a stable signal — a process that demands significant training and experience.

The NeuraSignal NG2 Intelligent Ultrasound eliminates this barrier through robotics and artificial intelligence. The NG2’s automated signal acquisition algorithm mimics the search pattern of an expert TCD sonographer but responds to real-time data, automatically finding the temporal window and locking onto the strongest cerebral blood flow signal. Studies have shown that the signal acquisition time and accuracy of the NG2 are comparable to an expert TCD sonographer.

For clinic directors, this means:

Reduced staffing requirements: CVR exams can be performed by a wider range of healthcare providers, not just specialized TCD sonographers.
Standardized exam quality: Automated acquisition reduces variability between operators, ensuring consistent, reliable results.
Scalable throughput: More exams can be performed per day with fewer personnel, improving clinic efficiency and revenue potential.
Faster time to competency: New staff can be trained on the NG2 platform quickly, reducing onboarding time and costs.

The NG2 is FDA-cleared and meets ISO 13485:2016 standards, giving clinic directors confidence in regulatory compliance. Combined with NG View — NeuraSignal’s secure, cloud-based platform for accessing dynamic exam data — the system supports remote interpretation and multi-site coordination, further extending its clinical utility.

Building a Business Case for TCD-Based CVR Assessment

For healthcare decision-makers evaluating the addition of TCD to their clinic, the value proposition extends beyond clinical outcomes:

Revenue diversification: TCD exams are reimbursable and can be added to existing neurology, cardiology, or vascular surgery workflows.
Comprehensive Stroke Center requirements: TCD is required for Comprehensive Stroke Center certification, making it a strategic investment for hospitals pursuing or maintaining this designation.
Reduced downstream costs: Early identification of impaired CVR can guide preventive interventions, potentially reducing costly emergency stroke admissions and ICU stays. Research has shown that TCD-guided management of post-SAH patients can reduce ICU stays by an average of 8 days — approximately $24,000 per patient.
Competitive differentiation: Offering advanced cerebrovascular diagnostics positions your clinic at the forefront of neurological care.

Take the Next Step in Cerebrovascular Diagnostics

Cerebrovascular reactivity assessment is rapidly moving from a research tool to a clinical imperative. With growing evidence linking impaired CVR to stroke, TBI outcomes, and dementia progression, clinics that adopt TCD-based CVR testing today are positioning themselves to deliver better patient outcomes, meet evolving accreditation standards, and capture new revenue streams.

NeuraSignal’s automated TCD technology makes this transition practical and scalable — removing the traditional barriers of operator dependency and specialized training while delivering exam quality comparable to expert sonographers.

Ready to see how automated TCD fits into your clinic’s workflow? Reach out to NeuraSignal to schedule a live demo and discover how the NG2 Intelligent Ultrasound can transform your cerebrovascular diagnostics program. Their team of specialists will walk you through the platform, answer your questions, and help you evaluate the clinical and operational impact for your practice.